Heres a look at Morningstars take on key obesity drug developers and their stocks: Eli Lilly LLY Fair Value Estimate: $540.00 Morningstar Rating: 2 stars Morningstar Economic Moat Rating: Wide Morningstar Uncertainty Rating: High We are raising our Eli Lilly fair value estimate to $540 from $500 following stronger-than-expected first-quarter results
[5] [7] Some patients may experience increased flatulence or loose stools
Serious reactions, such as breathing difficulty or severe dizziness, require immediate medical attention
The trademarks included in this document are owned by each respective company, used for informational purposes only, and do indicate any endorsement or affiliation
The FDA has granted them a fast-track designation to accelerate the process
Only women planning pregnancy, pregnant, and breastfeeding patients should take additionally approximately 150 g/d of iodine (as KI) in tablets [90]